COVID-19: Genetic Factors Influencing Susceptibility and Severity

Genetics partially explains why SARS-CoV-2 infection ranges from asymptomatic to fatal. Large-scale GWAS and sequencing studies have identified loci affecting susceptibility, severity, and long COVID. These insights illuminate biology and potential therapeutic targets.

Key Genetic Discoveries

1. Susceptibility to Infection

  • ABO blood group: Blood group A ↑ susceptibility (OR ~1.2); O ↓ risk (OR ~0.8). Mechanism: anti-A antibodies may block viral adhesion; glycosylation differences.
  • ACE2 variants: Rare missense variants (e.g., p.Arg514Gly) reduce viral binding in vitro. eQTLs lowering ACE2 expression may protect.
  • TMPRSS2 variants: Regulate viral entry protease; some variants alter expression.

2. Severity (Critical Illness)

COVID-19 Host Genetics Initiative (HGI) meta-analyses (>50,000 cases, 2M controls) identified 23+ genome-wide significant loci:

  • 3p21.31 (LZTFL1, CCR9, FYCO1, SLC6A20, XCR1): Strongest signal. Risk haplotype (Neanderthal-derived) ↑ risk 1.3–1.7× per allele. LZTFL1 modulates epithelial response; CCR9/CXCR6 affect immune cell trafficking.
  • 9q34.2 (ABO): Confirmed for severity (A ↑, O ↓).
  • 19p13.2 (DPP9): Risk allele ↑ DPP9 expression → inflammasome activation, pyroptosis.
  • 21q22.1 (IFNAR2, IL10RB, IFNAR1): Protective alleles ↑ type I interferon signaling — critical early antiviral defense.
  • 12q24.13 (OAS1/2/3): Splice variant (rs10774671-G) → longer OAS1 isoform → enhanced RNase L activation → viral RNA degradation. Protective.
  • TYK2: Risk variant (rs11085727) ↓ TYK2 function → impaired IFN signaling. JAK inhibitor target (baricitinib approved).
  • IFNAR2, IL10RB, CCR2, CXCR6, ABO, DPP9, TYK2, OAS1/3, LZTFL1 — converge on innate antiviral immunity and inflammatory lung injury.

3. Long COVID (PASC)

  • Emerging loci: FOXP4 (lung function, immune regulation), HLA-DQA1/HLA-DQB1 (antigen presentation), IL10RB.
  • Shared genetics with fatigue, autoimmunity, cardiometabolic traits.

Clinical Translation

  • Risk stratification: Polygenic risk scores (PRS) + clinical factors → identify high-risk for early intervention (e.g., antiviral, Evusheld historically).
  • Drug repurposing: Baricitinib (JAK1/2 inhibitor) targets TYK2 pathway; approved for hospitalized COVID. Trials of IFN-β, DPP9 inhibitors.
  • Vaccine response: HLA variants influence antibody titers; IFNAR2 variants affect reactogenicity.

Limitations & Context

  • Genetics explains ~10–20% of severity variance; age, comorbidities, vaccination, access to care dominate.
  • Most variants are common (MAF >1%) with modest effect (OR 1.1–1.3).
  • Population diversity: most GWAS in European ancestry; trans-ancestry meta-analyses improving.
  • Not deterministic — no "COVID gene" for clinical testing.

Genetics reveals mechanism, not destiny. Public health measures and vaccination remain the great equalizers.

Genetic Disorders - Related Articles